-
How Endo's FDA Committee Vote Affects Egalet
Wednesday, March 15, 2017 - 10:38am | 368Read More...“After two days of data presentations, the FDA Advisory Committee voted 18-8 (1 abstention) that the benefits of reformulated, crush-resistant Opana ER no longer outweigh the risks,” Cantor Fitzgerald’s Chiara Russo said in a note. The analyst maintained an Overweight rating on...
-
For Egalet, Clinical Delays Outweigh Solid Q4 And Arymo Launch
Monday, March 13, 2017 - 1:45pm | 305Read More...Cantor Fitzgerald cut its price target on Egalet Corp (NASDAQ: EGLT) shares by $2 to $13 on the delay of clinical progress for Egalet-002, which is now expected to file an NDA in 2019 versus previous guidance of mid-2017. However, Chiara Russo maintained an Overweight rating on the stock, given the...
-
Egalet's Best-In-Class Opioid Abuse Deterrent Continues To Impress
Monday, December 19, 2016 - 12:24pm | 266Read More...Cantor Fitzgerald reiterated its Overweight rating on Egalet Corp (NASDAQ: EGLT) after it announced positive data of Egalet-002, in a Category 3, intranasal human abuse potential (HAP) study. Egalet-002, based on the company’s Guardian technology, is in late-stage development for the...
-
The FDA's Historic Caution On Abuse Deterrent Labeling
Friday, November 25, 2016 - 12:18pm | 408Read More...Before the market open on Friday, IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI)reported its NDA submission for its abuse-deterrent Rexista (oxycodone hydrochloride) extended release tablets designed in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths. "The NDA submission of...
-
Why Egalet Investors Should Expect FDA Approval On Arymo By Year-End
Monday, November 7, 2016 - 12:10pm | 253Read More...Egalet Corp’s (NASDAQ: EGLT) proprietary abuse-deterrent extended-release morphine formulation, Arymo ER, will likely be approved by the end of this year, Cantor Fitzgerald’s Chiara Russo said in a report. She maintained a Buy rating on the company, with a price target of $21....
-
Why Egalet's FDA PDUFA Delay Is No Cause For Panic
Monday, October 17, 2016 - 1:20pm | 370Read More...Shares of Egalet Corp (NASDAQ: EGLT) traded lower by more than 5 percent Monday morning after a scheduled meeting with the U.S. Food and Drug Administration (FDA) to discuss its delayed ARYMO ER therapy. Egalet said in a press release that the FDA "has identified no particular issue with our...
-
Importance Of Phase 2 Trials
Monday, July 25, 2016 - 9:14am | 515Read More...Healthcare and pharmaceutical companies begin evaluating a drug they wish to sell to the public through a series of clinical trials. A Phase I trial consists of a company testing its drug or therapy on a small group of 20 to 100 healthy volunteers. Chiara Russo, a stock analyst for Cantor...
-
Importance Of Phase 1 Trials
Friday, July 22, 2016 - 2:18pm | 458Read More...Pharmaceutical companies are naturally in the business of selling a drug or therapy to patients suffering from an illness in disease. The process is often lengthy, expensive and could result in companies declaring bankruptcies — or reaping hundreds of millions of dollars in profit. For very...
-
Cantor Raises Price Target For Paratek Pharma, Sees 82% Upside
Friday, June 17, 2016 - 5:08pm | 299Read More...Cantor Fitzgerald has raised its price target on the shares of Paratek Pharmaceuticals Inc (NASDAQ: PRTK) to $30 (82 percent upside) from $27 after the company announced positive data from the Phase 3 trial of Omadacycline in acute bacterial skin and skin structure infections (ABSSSI). The...
-
Cantor Doesn't Think BioDelivery Sciences Should Be Cutting To Grow, Downgrades Stock To Hold
Wednesday, May 11, 2016 - 9:52am | 267Read More...BioDelivery Sciences International, Inc. (NASDAQ: BDSI) reported in-line 1Q16 EPS of ($0.36). Cantor Fitzgerald’s Chiara Russo downgraded the rating for the company from Buy to Hold, while reducing the price target from $9 to $5. The analyst commented that while there seems to be “...
-
Cantor Initiates Heron Therapeutics With Buy Rating, $41 Price Target
Tuesday, May 3, 2016 - 9:00am | 316Read More...Cantor Fitzgerald’s Chiara Russo mentioned that with Heron Therapeutics Inc (NASDAQ: HRTX)'s lead product, Sustol, coming up for FDA approval, there was potential for a differentiated label that would cover both delayed and acute CINV (Chemotherapy-Induced Nausea and Vomiting). The analyst...
-
Proxy Battle: What's Happening Between Starboard And DepoMed?
Monday, April 25, 2016 - 4:28pm | 568Read More...Specialty pharmaceutical DepoMed Inc (NASDAQ: DEPO) received a significant boost in early April, following activist investment firm Starboard Value's disclosure of a significant stake in the company. Context Of Proxy Battle At the time of the disclosure, Starboard stated it had "significant...
-
DepoMed's Latest Acquisition: Too Good To Be True?
Wednesday, November 18, 2015 - 11:33am | 281Read More...Depomed Inc (NASDAQ: DEPO) shares have appreciated 26.13 percent year-to-date, although they are currently trading significantly below their 52-week high. Cantor Fitzgerald’s Chiara Russo has maintained a Buy rating and price target of $29 on the company. The company has announced...
-
Analyst Sees Success For Tonix Pharmaceuticals Holdings Corp.
Thursday, May 7, 2015 - 4:43pm | 262Read More...Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) lead drug candidate for fibromyalgia and post-traumatic stress disorder shows promise despite flunking a recent Phase IIb trial, an analyst said. Tonix, up about 5 percent in the past three months, changed hands recently at $6.06, up $0.06 cents....
